Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2025-01-05 Board/Management Inform…
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Letter to Percheron Therapeutics Limited Shareholders 4 pages 251.8KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 6 January 2025, consisting of a letter from the Board of Directors to shareholders of Percheron Therapeutics Limited. The letter discusses the negative topline results from a phase IIb clinical trial and outlines the company's strategic plans going forward. It is addressed directly to shareholders and signed by board members. The content is a communication from the board explaining recent developments and future intentions, rather than a formal financial report or regulatory filing. The document is not a full annual or interim report, audit report, earnings release, or other detailed financial disclosure. It is also not a proxy solicitation, voting results announcement, or management discussion and analysis. The letter is a direct communication from the board to shareholders, which fits the category of Board/Management Information (MANG), as it announces the board's perspective and plans following a significant event. The document length (8156 characters) supports it being a substantive letter rather than a brief announcement or report publication notice. Therefore, the best classification is MANG with high confidence.
2025-01-05 English
Becoming a substantial holder from PVL 2 pages 227.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 filed under the Corporations Act 2001, titled 'Notice of initial substantial holder'. It details the substantial shareholding of Powerhouse Ventures Limited in Percheron Therapeutics Limited, including voting power, relevant interests, acquisition dates, and consideration paid. This type of filing is a notification of a major shareholding or change in significant share ownership levels, which aligns with the category 'Major Shareholding Notification'. The document is about reporting shareholding thresholds being crossed, not about financial results, management changes, or other report types.
2025-01-05 English
Change of Director's Interest Notice-Dr Charmaine Gittleson 2 pages 220.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the interest, and transaction details. This matches the description of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 3743 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, earnings release, or any other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2024-12-30 English
Change of Director's Interest Notice - Dr James Garner 2 pages 221.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is a 'Change of Director's Interest Notice' filed under ASX listing rule 3.19A.2. It details the acquisition of shares and options by a director, including dates, quantities, and values. This type of document reports personal share transactions by company directors and executives, which matches the definition of 'Director's Dealing' filings. There is no indication that this is a full financial report, management announcement, or other category. The document length and content confirm it is a detailed insider transaction report, not a brief announcement or certification.
2024-12-26 English
Notification of cessation of securities - PER 4 pages 15.5KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry or lapse) of certain securities (options) for Percheron Therapeutics Limited. It includes specific information about the securities that have ceased, reasons for cessation, dates, and the updated issued capital following these changes. This is a regulatory announcement related to changes in the company's issued securities, specifically the cessation of certain options. It is not a full financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of a regulatory announcement about securities cessation, which aligns best with the 'Regulatory Filings' (RNS) category as a general regulatory announcement that does not fit other more specific categories like share issue or capital change (SHA) or transaction in own shares (POS). Given the nature of the document as a formal notification to the exchange about securities cessation, the classification is Regulatory Filings (RNS) with high confidence.
2024-12-19 English
Change of Director's Interest Notice-Dr Charmaine Gittleson 2 pages 220.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the disposal of unquoted options and the expiry of options. The content focuses exclusively on the director's personal share transactions and interests, with no financial performance data or company-wide reports. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3832 characters, which is consistent with a detailed notice rather than a full report. Therefore, the correct classification is DIRS.
2024-12-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.